HIV and hepatitis C virus (HCV) are a major cause of morbidity and mortality, and both viruses contain high genomic variation. To date, viral gene sequencing has been handled by standard Sanger sequencing (SSS) for the detection of specific drug-resistance determinants for HIV and HCV. However, SSS-derived information is limited. By contrast, full-length viral gene sequences when linked to clinical data might influence the monitoring of drug resistance to optimally guide treatment, identify sources of viral transmissions within health-care settings, and track emerging epidemics. The ICONIC (Infection Response through Virus Genomics) study aims to introduce a novel method called next generation sequencing (NGS) within UK health-care settings, testing potential implementation in routine practice. With use of samples within established diagnostic laboratory workflows, NGS has the potential to produce higher informational content than SSS and report in a timely fashion. However, economic evidence for this emerging method is scarce. Aims To use the examples of HIV and HCV to compare the cost of NGS versus SSS.
Cost analysis of standard Sanger sequencing versus next generation sequencing in the ICONIC study
Viral infections represent a significant burden to the NHS and a continuing threat to human health with national treatment and care costs for influenza pandemics for example in excess of £2billion. The effect of virus outbreaks is difficult to calculate because of the often very constraint time windows in which patients and their linked data need to be processed, interpreted and actioned upon and the high number of related patient co-morbidities.
Until recently the investigation of viral transmission during an outbreak was challenging as molecular typing models such as Sanger Sequencing (SSS) had low discriminatory power and their informative value on infection control measures was limited, resulting in reduced outbreak containment and increasing healthcare costs. This is set to change with Next Generation Sequencing (NGS) which provides the maximum possible discrimination between closely related viral strains. Here we present the preliminary results from the Infection Control through Viral Genomics (ICONIC) project, a flagship Health Innovation Challenge Fund project with the aim or introducing NGS processes into routine NHS operations for the effective detection and surveillance of viruses and improved stratification of patients. 
